[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334453-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334453-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","recent-nanotheranostic-approaches-in-cancer-research","Recent nanotheranostic approaches in cancer research","","Cancer remains a major cause of premature death worldwide. Nanotheranostics combines therapeutics and diagnostics to track treatment response while improving drug efficacy and safety. The review surveys recent cancer imaging and diagnostic tools, including MRI, CT, PET, SPECT, and PAT, and explains how targeting mechanisms interact with tumor cells. It evaluates current nanotheranostic platforms and agents such as gold nanoparticles, silica, liposomes, dendrimers, and metal-based systems, including their limitations and relevance to theranostics.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/recent-nanotheranostic-approaches-in-cancer-research/334453/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/recent-nanotheranostic-approaches-in-cancer-research/334453.png","ImageObject",300,407,{"name":42,"@type":43},"Logic","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is nanotheranostics and what problem does it aim to address?","Question",{"text":63,"@type":64},"Nanotheranostics integrates therapeutics and diagnostics to monitor treatment response and improve drug efficacy and safety. It aims to better support cancer detection and therapy by linking imaging with targeted treatment delivery.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which imaging and diagnostic tools are discussed for cancer diagnostics?",{"text":68,"@type":64},"The review discusses molecular imaging tools including MRI, CT, PET, SPECT, and PAT for cancer diagnostics. It also emphasizes how these tools relate to receptor binding and internalization processes in cancer cells.",{"name":70,"@type":61,"acceptedAnswer":71},"What types of nanotheranostic agents are highlighted and what are their limitations?",{"text":72,"@type":64},"Gold nanoparticles, silica, liposomes, dendrimers, and metal-based agents are emphasized. The review also highlights that different agents face limitations, motivating the use of multifunctional and hybrid nanoparticles for theranostic performance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334453,1790473353,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":113,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Clinical and Experimental Medicine (2024) 24:8  \n[https://doi.org/10.1007/s10238-023-01262-3](https://doi.org/10.1007/s10238-023-01262-3)  \nRecent nanotheranostic approaches in cancer research  \nDeepshikha Gupta1 · Priyanka Roy2 · Rishabh Sharma1 · Richa Kasana1 · Pragati Rathore1 ·  \nTejendra Kumar Gupta1  \nReceived: 10 August 2023 / Accepted: 7 December 2023 / Published online: 19 January 2024 © The Author(s) 2024  \nAbstract  \nHumanity is suffering from cancer which has become a root cause of untimely deaths of individuals around the globe in the recent past. Nanotheranostics integrates therapeutics and diagnostics to monitor treatment response and enhance drug efficacy and safety. We hereby propose to discuss all recent cancer imaging and diagnostic tools, the mechanism of targeting tumor cells, and current nanotheranostic platforms available for cancer. This review discusses various nanotheranostic agents and novel molecular imaging tools like MRI, CT, PET, SPEC, and PAT used for cancer diagnostics. Emphasis is given to gold nanoparticles, silica, liposomes, dendrimers, and metal-based agents. We also highlight the mechanism of targeting the tumor cells, and the limitations of different nanotheranostic agents in the field of research for cancer treatment. Due to the complexity in this area, multifunctional and hybrid nanoparticles functionalized with targeted moieties or anti-cancer drugs show the best feature for theranostics that enables them to work on carrying and delivering active materials to the desired area of the requirement for early detection and diagnosis. Non-invasive imaging techniques have a specificity of receptor binding and internalization processes of the nanosystems within the cancer cells. Nanotheranostics may provide the appropriate medicine at the appropriate dose to the appropriate patient at the appropriate time.  \nGraphical abstract  \nKeywords Nanotheranostics · Cancer · Molecular imaging · Diagnostics · AuNP  \nExtended author information available on the last page of the article  \nIntroduction  \nCancer is a serious and often life-threatening disease characterized by the uncontrolled growth and spread of abnormal cells in the body. It can have a profound impact on individuals and their families, as it can be physically, emotionally, and financially challenging. The second most common cause of death after a heart attack is cancer despite the great breadth of knowledge and information about it and improvements in its treatment. According to the International Agency for Research on Cancer (IARC), there were 19.3 million new cancer cases reported, and 9.9 million people died from cancer in 2020. In a study carried out by Zaorsky et al. [1] in the year 2016 based on US death certificate data from years 1973–2012, indexcancer, non-index-cancer, and noncancer causes for deaths of cancer patients were categorized. The group of people  \nwith malignancies of the testis, kidney, bladder, endometrial, breast, cervix, prostate, ovary, anus, colorectum, melanoma, and lymphoma saw the highest relative drop in index-cancer death (usually from > 60% to 30%) . Patients with malignancies of the liver, pancreatic, esophagus, lung, and brain showed stable index-cancer deaths (usually > 40%) . Patients with malignancies of the colorectum, bladder, kidney, endometrial, breast, prostate, and testis had the greatest noncancer causes of mortality; > 40% of fatalities were due to heart disease. As per the detail given by IARC, the estimated increase in the new cases from 2020 to 2025, and 2020 to 2040 would be 21.6 million, and 28.9 million, respectively (considering the age of the people from 0 to 85+) . Figure 1 represents the reported types of cancer incidences and mortality in both sexes across the world in the year 2020 pointing that the most prevalent cancer type in females is breast cancer while in males lung  \n\n| Liver Rectum Ovary Stomach Corpus uteri Colon Thyroid Cervix uteri Lung Breast\u003Cbr>Leukaemia\u003Cbr>Non-Hodgk","cbCaicFfQa8cPFBA","https://ap.wps.com/l/cbCaicFfQa8cPFBA","pdf",2553590,"English","# Introduction\n## Cancer burden and epidemiology\n## Theranostics and personalized medicine concepts\n## Rationale for nanotheranostic imaging and targeting","[{\"question\":\"What is nanotheranostics and what problem does it aim to address?\",\"answer\":\"Nanotheranostics integrates therapeutics and diagnostics to monitor treatment response and improve drug efficacy and safety. It aims to better support cancer detection and therapy by linking imaging with targeted treatment delivery.\"},{\"question\":\"Which imaging and diagnostic tools are discussed for cancer diagnostics?\",\"answer\":\"The review discusses molecular imaging tools including MRI, CT, PET, SPECT, and PAT for cancer diagnostics. It also emphasizes how these tools relate to receptor binding and internalization processes in cancer cells.\"},{\"question\":\"What types of nanotheranostic agents are highlighted and what are their limitations?\",\"answer\":\"Gold nanoparticles, silica, liposomes, dendrimers, and metal-based agents are emphasized. The review also highlights that different agents face limitations, motivating the use of multifunctional and hybrid nanoparticles for theranostic performance.\"}]","Recent nanotheranostic approaches in cancer research | PDF",1790006733,76]